Characteristics of COVID-19 Infection in a Hospitalized Autoimmune Hepatitis Patient

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a major public health worldwide. Hepatic dysfunction has been seen in patients with COVID-19 and could be related to a viral cytopathic effect, an exacerbated immune r...

Descripción completa

Detalles Bibliográficos
Autores principales: da Costa, Vanessa Duarte, Wiggers, Wilian Jean, Ivantes, Claudia Alexandra Pontes, da Fonseca, Rodrigo Jardim Monteiro, Dávila, Alberto Martín Rivera, Moreira, Otacilio C., Ferreira, Beatriz Iandra da Silva, de Paula, Vanessa Salete, da Silva, Lucas Lima, Santos, Alanna Calheiros, Villar, Livia Melo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501835/
https://www.ncbi.nlm.nih.gov/pubmed/36145486
http://dx.doi.org/10.3390/pathogens11091054
Descripción
Sumario:The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a major public health worldwide. Hepatic dysfunction has been seen in patients with COVID-19 and could be related to a viral cytopathic effect, an exacerbated immune reaction, or drug-induced liver damage. Currently, routine modification of immunosuppressive therapy in patients with autoimmune hepatitis (AIH) before and after SARS-CoV-2 infection remains an important topic to be discussed. However, there is little evidence about this thematic to support any recommendation. Here, we described a case report in which the use of an immunosuppressive drug by a patient with diagnosed AIH might have influenced the COVID-19 clinical course with altered laboratory hematological and biochemical parameters during infection.

Ejemplares similares